Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
| 대상 질환 | Lung Neoplasm |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Wake Forest University Health Sciences |
| 상태 | 완료 |
| 참여자 수 | 84 명 |
| 중재(약물) | risedronate, Matching placebo |
| 시작일 | 2019년 7월 12일 |
| 완료일 | 2022년 3월 2일 |
| 결과 공개일 | 2023년 7월 14일 |
요약
This is a double blind randomized controlled study investigating the efficacy of a single dose of 150 mg risedronate (a bone anti-resorptive) vs a single dose of placebo given prior to SBRT for peripheral lung tumors that are within 2 cm of the chest wall. Our hypothesis is that the use of a single dose of 150 mg risedronate will eliminate or greatly reduce the rapid bone loss that occurs with radiation induced early osteoclast recruitment/activation. Patients will be given either a single dose of 150 mg risedronate or placebo at the time of their treatment mapping "simulation" CT scan. Typically, radiation treatments begin at 1 - 3 weeks following this mapping scan, as each treatment plan requires detailed physics calculations and quality assurance checks. All CT imaging referenced below is performed as a routine standard of care surveillance and is necessary for cancer treatment follow-up. These chest CT scans that are utilized in this research protocol would be performed every 3 months regardless of inclusion on this trial.
Changes in Mean Cortical Thickness
| Risedronate | 4.24 ± 3.04 percent change in mm cortical thickne |
|---|---|
| Matching Placebo | 7.14 ± 2.93 percent change in mm cortical thickne |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer — M.D. Anderson Cancer Center
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)